Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS7901584 B2
Publication typeGrant
Application numberUS 12/476,838
Publication dateMar 8, 2011
Filing dateJun 2, 2009
Priority dateFeb 7, 2005
Fee statusPaid
Also published asEP1848473A1, EP1848473B1, US7553413, US20060175268, US20090236297, WO2006086200A1
Publication number12476838, 476838, US 7901584 B2, US 7901584B2, US-B2-7901584, US7901584 B2, US7901584B2
InventorsRandel Dorian, Michael D. Leach, Richard W. Storrs
Original AssigneeHanuman, Llc, Biomet Biologics
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Plasma concentration
US 7901584 B2
Abstract
A plasma concentrator having a concentrator chamber, concentrator gel beads, a filter, and an agitator. The agitator end is positioned in the concentrator chamber and supported for rotation about its central axis and for reciprocal movement along its central axis. A filter is selected to block effective flow of plasma therethrough under ambient gravity conditions and permit plasma and plasma concentrate flow therethrough under centrifugal forces of the separation gravity. A method concentrates plasma by removing water without significantly denaturing the fibrinogen in the plasma. Then centrifugal force can be applied to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads.
Images(5)
Previous page
Next page
Claims(24)
1. A method for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma, comprising:
positioning a plurality of concentrator gel beads in a concentrator chamber of the plasma concentrator;
positioning a sample volume of plasma in the concentrator chamber of the plasma concentrator;
moving an actuator stem having a lower agitator end to agitate the sample volume of plasma and the concentrator gel beads in the concentrator chamber with agitator blades extending outwardly from the lower agitator end being positioned in the concentrator chamber;
concentrating the plasma by removing at least a portion of water from the sample volume of plasma to the concentrator gel beads to form a concentrated plasma volume; and
removing the concentrated plasma volume through a filter in a lower opening of the concentrator chamber;
wherein the concentrator chamber includes a top with an upper opening through which an upper end of the actuator stem extends.
2. The method of claim 1, wherein moving the agitator stem at least one of rotating the agitator about its central axis and reciprocally moving the agitator stem about its central axis.
3. The method of claim 1, further comprising agitating the sample volume of plasma and the concentrator gel beads including moving the total volume of the sample volume of plasma and the concentrator gel beads at least by moving the agitator blades near a cylindrical inner wall of the concentrator chamber and the agitator blades have an outer edge in close proximity to the inner wall with a space between the outer edge and the inner wall being less than a diameter of the gel beads.
4. The method of claim 1, further comprising:
limiting or eliminating upward axial movement by contacting a stop sleeve extending from a top of the concentrator into the concentrator chamber with stop projections of the agitator stem,
wherein the stop sleeve has a lower abutment surface and the stop projections extend outward beyond the diameter of the stop sleeve, an upper surface of the stop projections positioned to stop upward axial movement of the agitator when contacting a lower abutment surface of the stop sleeve.
5. The method of claim 4, further comprising:
limiting or eliminating downward movement of the agitator by contacting an upper surface of the filter with a lower surface of the agitator blades; and
sweeping the upper surface of the filter by contacting the upper surface of the filter with the lower surface of the agitator blades;
wherein the downward motion of the blades during the reciprocal movement of the agitator being arrested by abutment with the upper surface of the filter.
6. The method of claim 1, further comprising:
blocking effective flow of plasma through the filter under ambient gravity conditions, but permitting free plasma concentrate flow therethrough under centrifugal forces at the separation gravity.
7. The method of claim 6, wherein the separation gravity is greater than 10 g's.
8. The method of claim 1, further comprising:
removing the plasma concentrate from the plasma concentrator through a plasma concentrate outlet conduit from a plasma concentrate reservoir;
wherein removing the plasma concentrate from the plasma concentrate reservoir includes moving the plasma concentrate from a sump formed in a floor of the plasma concentrate reservoir.
9. The method of claim 8, further comprising:
wherein introducing plasma includes introducing up to 50 mL of plasma into concentration chamber.
10. The method of claim 8, wherein removing water from the plasma includes forming a plasma concentrate having a protein concentration 1.5 to 3 times greater than the protein concentration of the untreated plasma.
11. A method for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma, comprising:
a) introducing the plasma into a concentration chamber containing a plurality of dehydrated concentrator gel beads and an agitator;
b) removing water from the plasma until the plasma has a protein concentration greater than the protein concentration of the untreated plasma while:
i) rotating the agitator to stir the beads while they are absorbing water from the plasma to reduce plasma polarization, and
ii) moving the agitator to break up clumps of beads that form during the stirring; and
c) applying centrifugal force to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads.
12. The method of claim 11, wherein the agitator having has agitator blades extending outwardly from its lower end, wherein the agitator is supported for rotation about its central axis and for reciprocal movement along its central axis.
13. The method claim 12, wherein the agitator blades rest on the upper surface of a filter, the agitator blades have a lower portion that sweeps the upper surface of the filter during rotation, and impacts the upper surface of the filter during reciprocal motion of the agitator along its central axis, wherein the agitator is rotated to sweep the upper surface of the filter and stirring beads resting thereupon to reduce plasma polarization, and the agitator is moved in a reciprocal motion to impact the upper surface of the filter and bead clumps forming on the surface during the stirring.
14. The method of claim 13, wherein the filter has a pore that blocks effective flow of plasma therethrough under ambient gravity conditions and permits plasma and plasma concentrate flow therethrough under forces of the centrifugal force.
15. The method of claim 12, wherein rotating the agitator and the agitator blades is performed by engaging a central agitator post from which the agitator blades extend;
wherein the central agitator post extends out of the concentration chamber.
16. A method for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma, comprising:
a) introducing the plasma into a concentration chamber containing a plurality of dehydrated concentrator gel beads and an agitator;
b) removing water from the plasma until the plasma has a protein concentration greater than the protein concentration of the untreated plasma while:
i) moving the agitator to cause agitation of the beads while they are absorbing water from the plasma to reduce plasma polarization, and
ii) moving the agitator to break up clumps of beads that form during the agitation; and
c) applying centrifugal force to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads; wherein moving the agitator includes rotating the agitator around a central axis of the agitator and reciprocally moving the agitator its along the central axis.
17. The method of claim 16, further comprising:
blocking effective flow of plasma through a filter under ambient gravity conditions, but permitting free plasma concentrate flow therethrough under centrifugal forces at a separation gravity.
18. The method of claim 17, wherein applying the centrifugal force to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads includes:
placing the plasma concentrator in a receptor of a centrifuge;
applying centrifugal forces to the plasma concentrator with the centrifuge;
removing the plasma concentrate from the surface of the gel beads, and
causing the plasma concentrate to flow through the filter.
19. The method of claim 18, wherein applying centrifugal forces to the plasma concentrator includes applying at least 10 g's of force to cause the plasma concentrate to flow through the filter.
20. The method of claim 19, further comprising:
collecting the concentrated plasma in a plasma concentrate reservoir positioned downstream of the flow of the plasma concentrate through the filter, but within the plasma concentrator.
21. The method of claim 20, further comprising:
removing the plasma concentrate from the plasma concentrator through a plasma concentrate outlet conduit extending from a plasma concentrate reservoir and integrated with the plasma concentrator.
22. The method of claim 21, further comprising:
moving the plasma concentrate to a sump formed in a floor of the plasma concentrate reservoir;
wherein the plasma concentrate outlet conduit is in fluid communication with the sump.
23. A method for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma, comprising:
a) introducing the plasma into a concentration chamber containing a plurality of dehydrated concentrator gel beads and an agitator;
b) removing water from the plasma until the plasma has a protein concentration greater than the protein concentration of the untreated plasma while:
i) moving the agitator to cause agitation of the beads while they are absorbing water from the plasma to reduce plasma polarization, and
ii) moving the agitator to break up clumps of beads that form during the agitation; and
c) applying centrifugal force to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads;
wherein moving the agitator includes moving the total volume of the plasma and the concentrator gel beads at least because the concentration chamber has a cylindrical inner wall and an agitator blade of the agitator has an outer edge in close proximity to the inner wall with a space between the outer edge and the inner wall being less than a diameter of the gel beads.
24. A method for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma, comprising:
a) introducing the plasma into a concentration chamber containing a plurality of dehydrated concentrator gel beads and an agitator;
b) removing water from the plasma until the plasma has a protein concentration greater than the protein concentration of the untreated plasma while:
i) moving the agitator to cause agitation of the beads while they are absorbing water from the plasma to reduce plasma polarization, and
ii) moving the agitator to break up clumps of beads that form during the agitation; and
c) applying centrifugal force to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads;
(d) limiting upward movement of the agitator by contacting a stop sleeve extending from a top of the plasma concentrator into the concentration chamber with stop projections of an agitator stem of the agitator, wherein the stop sleeve has a lower abutment surface and the stop projections extend outward beyond the diameter of the stop sleeve, an upper surface of the stop projections constituting abutment surfaces positioned to stop upward axial movement of the agitator when contacting a lower abutment surface of the stop sleeve;
(e) limiting downward movement of the agitator by contacting an upper surface of a filter with a lower surface of agitator blades of the agitator; and
(f) sweeping the upper surface of the filter by contacting the upper surface of the filter with the lower surface of the agitator blades;
wherein the downward motion of the agitator blades during the reciprocal movement of the agitator is arrested by abutment with the upper surface of the filter.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 11/342,982 filed on Jan. 30, 2006, now U.S. Pat. No. 7,553,413 issued on Jun. 30, 2009, which claims the benefit under 35 USC 120 of the filing date of U.S. Provisional Application No. 60/650,860 filed Feb. 7, 2005. The entire disclosures of the above applications are incorporated herein by reference.

FIELD

This invention relates to an apparatus and method for preparing a plasma concentrate that can be used as a tissue sealant and a hemostat. Then plasma concentrate is preferably free of cells.

BACKGROUND

This section provides background information related to the present disclosure which is not necessarily prior art.

Blood can be fractionated, and the different fractions of the blood can be used for different medical needs. Under the influence of gravity or centrifugal force, blood spontaneously sediments into three layers. At equilibrium, the top low-density layer is a straw-colored clear fluid called plasma. Plasma is a water solution of salts, metabolites, peptides, and many proteins ranging from small (insulin) to very large (complement components).

The bottom, high-density layer is a deep red viscous fluid comprising anuclear red blood cells (erythrocytes) specialized for oxygen transport. The red color is imparted by a high concentration of chelated iron or heme that is responsible for the erythrocytes' high specific gravity. The relative volume of whole blood that consists of erythrocytes is called the hematocrit, and in normal human beings this can range from about 37% to about 52% of whole blood.

The intermediate layer is the smallest, appearing as a thin white band above the erythrocyte layer and below the plasma layer; this is called the buffy coat. The buffy coat itself has two major components, nucleated leukocytes (white blood cells) and anuclear smaller bodies called platelets (or thrombocytes). Leukocytes confer immunity and contribute to debris scavenging. Platelets seal ruptures in blood vessels to stop bleeding, and deliver growth and wound healing factors to a wound site. Slower speed or shorter duration centrifugation permits separation of erythrocytes and leucocytes from plasma, while the smaller platelets remain suspended in the plasma, yielding platelet rich plasma (PRP).

A major improvement in making plasma concentrate from whole blood for use in wound healing and as a tissue sealant was described in U.S. Pat. No. 5,585,007; this patent is hereby incorporated by reference in its entirety. This device, designed for placement in a medical laboratory or surgical amphitheater, with an integral centrifuge used a disposable cartridge for preparing tissue sealant. The device was particularly applicable for stat preparations of autologous tissue sealants. Preparation in the operating room of 5 ml of sealant from 50 ml of patient blood required less than 15 minutes and only one simple operator step. There was no risk of tracking error because processing can be done in the operating room. Chemicals added could be limited to anticoagulant (e.g., citrate) and calcium chloride. The disposable cartridge could fit in the palm of the hand and was hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Adhesive and tensile strengths of the product were comparable or superior to pooled blood fibrin sealants made with precipitation methods. Use of antifibrinolytic agents (such as aprotinin) was not necessary because the tissue sealant contained high concentrations of natural inhibitors of fibrinolysis from the patient's blood. This new tissue sealant also optionally contained patient platelets and additional factors that promote wound healing, healing factors that are not present in commercially available fibrin sealants.

The patented device used a new sterile disposable cartridge with the separation chambers for each run. Since the device was designed to be used in a normal medical setting with ample power, the permanent components, designed for long-term durability, safety, and reliability, were relatively heavy, using conventional centrifuge motors and accessories.

Disposable plasma concentrating devices suitable for concentrating PRP according to this invention are described in commonly assigned, application Ser. No. 10/394,828 filed Mar. 21, 2003, now U.S. Pat. No. 6,905,612 issued on Jun. 14, 2005, the entire contents of which are hereby incorporated by reference. The cell-free plasma fraction is removed and discarded.

SUMMARY

This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.

The disposable device of this invention is suitable for preparing a highly valuable autologous plasma concentrate from cell-free plasma fractions.

The concentrating phase requires only simple manual manipulation (rotating the agitator shaft with reciprocal movement to disrupt gel bead clumping). The device is then spun with a conventional centrifuge to separate the plasma concentrate from the desiccated beads, moving the plasma concentrate from the concentrating zone into a plasma concentrate reservoir, from which it can be removed by a conventional applicator syringe.

The plasma concentrator of this invention comprises a concentrator chamber, a plurality of concentrator gel beads in the concentrator chamber, a filter, and an agitator. The agitator comprises an actuator stem having an upper agitator end and a lower agitator end, agitator blades extending outwardly from the lower end. The lower agitator end is positioned in the concentrator chamber, and mounted or supported for both rotation about its central axis and for reciprocal movement along its central axis. The concentrator has a top with an upper opening through which the upper end of the actuator stem extends, and a lower opening in which the filter is positioned. The concentrator chamber can have a cylindrical inner wall, and the agitator blades can have an outer edge in close proximity to the inner wall with the space between the outer edge and the inner wall being less than the diameter of the gel beads.

The upper opening of the concentrator can include a stop sleeve extending from the top of the concentrator into the concentrator chamber, the stop sleeve having a lower abutment surface. The agitator stem can have stop projections that extend outward beyond the diameter of the strop sleeve, the upper surfaces of the stop projections constituting abutment surfaces positioned to stop upward axial movement of the agitator when contacting the lower abutment surface of the stop sleeve.

The filter has an upper surface and the agitator blades can have a lower portion that contacts the upper surface of the filter and is positioned for sweeping the upper surface during rotation of the agitator and for making impact with the upper surface during downward movement of the agitator along its central axis. The downward motion of the blades during the reciprocal movement of the agitator can be arrested by abutment with the upper surface of the filter.

The filter is selected to block effective flow of plasma therethrough under ambient gravity conditions and permits plasma concentrate flow therethrough under centrifugal forces above 10 g's and up to at least as high as the separation gravity.

The plasma concentrator can be combined with a plasma concentrate outlet conduit and a plasma concentrate reservoir with an upper opening in communication with the filter and positioned to receive plasma concentrate passing through the filter. The plasma concentrator can have a sloping floor and a sump at the lowest end of the floor, one end of the plasma concentrate outlet conduit communicating with the sump.

The method of this invention for concentrating plasma by removing water without significantly denaturing the fibrinogen in the plasma can include introducing the plasma into a concentration chamber containing a plurality of dehydrated concentrator gel beads and an agitator. Then water is removed from the plasma until the plasma has a protein concentration greater than 1.5 times the protein concentration of the untreated plasma.

While the water is being removed, the agitator can be rotated to stir the beads to reduce plasma polarization and moved to break up clumps of beads that form during the agitation. Then centrifugal force can be applied to the concentrated plasma in an amount sufficient to separate a substantial portion of the plasma concentrate from the beads.

When the concentration chamber contains an agitator having agitator blades extending outwardly from its lower end, wherein the agitator is supported for rotation about its central axis and for reciprocal movement along its central axis, the agitator can be rotated to stir the beads while they are absorbing water from the plasma to reduce plasma polarization, and the agitator can be moved along its central axis in a reciprocal motion to break up clumps of beads that form during the agitation.

If the agitator blades rest on the upper surface of a filter, the agitator blades can have a lower portion that sweeps the upper surface of the filter during rotation, and impacts the upper surface of the filter during reciprocal motion of the agitator along its central axis. Then the agitator can be rotated to sweep the upper surface of the filter and stirring beads resting thereupon to reduce plasma polarization, and the agitator can be moved in a reciprocal motion to impact the upper surface of the filter and bead clumps forming on the surface during the stirring.

When the filter has pores that block effective flow of plasma therethrough under ambient gravity conditions and permits plasma and plasma concentrate therethrough at more than 10 g's and up to the separation gravity. The plasma can be maintained in contact with the beads by the filter during the water removal and plasma concentrate can be caused to flow through the filter when the mixture is subjected to centrifugal forces in the direction of the filter of as high as the separation gravity.

Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.

DRAWINGS

The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.

FIG. 1 is a front view of the plasma concentrating device of this invention;

FIG. 2 is a top view of the plasma concentrating device shown in FIG. 1;

FIG. 3 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 1 taken along the line 3-3 of FIG. 2;

FIG. 4 is a front view of the agitator component of the plasma concentrating device of this invention;

FIG. 5 is cross-sectional view of the agitator component show in FIG. 4, taken along the line 5-5;

FIG. 6 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 3, taken along the line 6-6;

FIG. 7 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 3 after plasma has been introduced into the device;

FIG. 8 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 7 after the gel beads have removed water from the plasma, swelling the beads;

FIG. 9 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 8 after centrifuging, wherein the plasma concentrate has flowed into the plasma concentrate reservoir; and

Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.

DETAILED DESCRIPTION

Example embodiments will now be described more fully with reference to the accompanying drawings.

The term “separation gravity” is a centrifugal force that is sufficient to separate plasma concentrate from the surface of the concentrator gel beads and to cause separated plasma concentrate to flow through the filter.

The device is one component of an improvement over the complex plasma separating and concentrating device described in U.S. Pat. No. 5,585,007. A disposable device described in application Ser. No. 10/394,828 filed Mar. 21, 2003, rapidly separates plasma from blood using a conventional medical laboratory centrifuge. The device of this invention converts the plasma into an autologous concentrate highly useful as a tissue sealant and hemostat.

Referring to the drawings, FIG. 1 is a front view of the plasma concentrating device of this invention, and FIG. 2 is a top view of the plasma concentrating device shown in FIG. 1. This small compact device is suitable for processing up to 50 ml of plasma. The concentrator 2 has an upper concentrator housing 4 and a lower concentrate reservoir housing 6. The upper concentrator housing 4 has a top 8 through which the agitator stem 10 of a gel bead agitator 12 (See FIGS. 3-5) extends. The top 8 also has a plasma inlet port 14 that extends through the top 8 and communicates with the concentration chamber 20 (FIG. 3) enclosed by the upper concentrating housing 4. A plasma concentrate outlet port 16 communicates with a plasma concentrate conduit 18 shown in greater detail in FIG. 3.

FIG. 3 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 1 taken along the line 3-3 of FIG. 2. FIG. 3 shows internal details of this device. The upper concentrator housing 4 encloses a concentrating chamber 20. The floor of the concentrating chamber 20 is filter 24, the upper surface of which supports desiccated concentrating gel beads 26.

The desiccated concentrating gel beads 26 can be insoluble beads or disks that will absorb a substantial volume of water and not introduce any undesirable contaminant into the plasma. They can be dextranomer or acrylamide hydrogel beads that are commercially available (Debrisan from Pharmacia and BIO-GEL P™ from Bio-Rad Laboratories, respectively). Alternatively, other concentrators can be used, such as SEPHADEX™ moisture or water absorbents (available from Pharmacia), silica gel, zeolites, cross-linked agarose, etc., in the form of insoluble inert beads. The beads are used in their desiccated state.

Gel bead agitator 12 is positioned with its bottom edge 28 resting on the top surface of filter base 24. Agitator stem 10 extends upward through a cylindrical stop sleeve 30 in the housing top 8. The stop sleeve 30 extends downward into the concentrating chamber 20 and service to support the agitator stem in a vertical orientation. The bottom edge surface 31 of the stop sleeve 30 constitutes a lower abutment surface. Integral projections 32 extend radially outward from the stirrer agitator stem 10 to a diameter larger than the inner diameter of the stop sleeve 30. The upper surfaces 33 of the projections 32 constitute upper abutment surfaces. As will be described in greater detail hereinafter, the gel bead agitator is rotated about its vertical axis and moved upward and downward in a reciprocal movement to stir the gel beads 26 during the water removal step. The contact of the low abutment edge 31 with the upper abutment surface 33 limits upward movement of the agitator blades or paddles 34 when they are raised during this reciprocal vertical movement of the stem 10.

Referring to FIGS. 3-5, the agitator comprises a plurality of paddles blades 34 extending radially outwardly from the central chamber stem 41. The outer vertical edge of the agitator blades are sized to make a sliding engagement with the inner surface 38 of the chamber housing 4 (FIG. 3). The distance between the outer edge of the paddles 34 and the inner surface 38 of the chamber housing should be smaller than the diameter of the individual gel beads to prevent individual gel beads from wedging between the agitator and the wall surface. Rotation of stem 10 about its central axis rotates the paddles 34 and stirs the beads 26.

FIG. 4 is a front view of the agitator component of the plasma concentrating device of this invention, and FIG. 5 is cross-sectional view of the agitator component show in FIG. 4, taken along the line 5-5.

The upper end of the stem 10 can optionally have a plurality of splines 39 that can mate with an optional agitator handle (not shown) or that can function as friction surfaces, facilitating manual rotation of the stem.

Referring to FIG. 3, the lower concentrate chamber housing 6 encloses a concentrate chamber 40 with a sloped bottom 41 leading to a sump or depression 42. The concentrate conduit 18 has a conduit end 44 that extends into the depression 42 to draw in most of the liquid concentrate (not shown) through the concentrate outlet 16 when the pressure in the conduit 18 is reduced.

The construction and function of the filter 24 is described in greater detail with respect to FIG. 6. FIG. 6 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 3, taken along the line 6-6.

The filter 24 is supported by a flat circular ring 46 and flat radial spokes 48. The openings in the support are designed to permit liquid flow through the filter under the pressure of centrifugal force. The filter must retain the plasma above the filter under ambient gravity during the water removal phase and permit plasma concentrate flow therethrough at centrifugal pressures used in the separation. Therefore the filter should retain fluid for at least up to 10 g's and permit flow at the separation gravity. The separation gravity is created when the system is spun in a centrifuge, the centrifugal force being directed in the axial direction through the filter. The higher the centrifugal force applied is during the plasma concentrate separation, the more effective the recovery of the plasma concentrate.

The concentration process has as its critical objective, the removal of water from the plasma without significantly denaturing the fibrinogen component of the plasma. This component provides effective the clotting action of blood and provides the sealing, adhesive and homeostatic properties of the concentrate.

The process is illustrated in FIGS. 7-9 wherein FIG. 7 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 3 after plasma has been introduced into the device; FIG. 8 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 7 after the gel beads have removed water from the plasma, swelling the beads; and FIG. 9 is a cross-sectional drawing of the plasma concentrating device shown in FIG. 8 after centrifuging, wherein the plasma concentrate has flowed into the plasma concentrate reservoir.

In the first step of the process, blood plasma 52 (preferably cell free) is introduced into the concentrating chamber 20 through the plasma inlet port 14. The plasma 52 entering the chamber 20 flows to the bottom of the chamber where it contacts the gel beads 26 as shown in FIG. 7.

As the gel beads 26 remove water from the plasma, the plasma contacting each bead's surface thickens, creating gel polarization that it impedes water absorption by the bead. Furthermore, as the thickened plasma becomes more viscous, the beads tend to clump. To disrupt the thickened plasma layer forming on each bead, the agitator stem 10 is rotated around its central axis, moving the agitator blades 34 through the beads and stirring the beads. To break up bead clumps, the agitator blades 34 can be raised and lowered by reciprocal motion of the agitator stem 10 along its central axis, the bottom edges 28 of the blades (FIG. 3) impact the bead clumps against the filter surface disrupting the clumps. The vertical movement of the agitator blades is limited to a range established by the upper surface of the filter 24 range of movement is defined by the floor 4 of the chamber and impingement contact between the abutments 31 and 33. The water swollen beads 53 and the concentrated plasma 54 are shown in FIG. 8. During this concentration stage, the plasma and its components can be concentrated to a concentration of from 1.5-3 times or higher than its original concentration.

The device of this invention is then placed in the cup receptors of a conventional laboratory centrifuge (not shown) and spun at a speed that will create a separation gravity, that is, a centrifugal force that will remove plasmas concentrate from the surface of the gel beads, and cause the plasma concentrate to flow through the filter. The filter can be constructed to allow flow of liquid therethrough at pressures above 10 g's. The centrifugal pressure forces of the plasma concentrate to flow from the bead surface through the filter 24 and into the plasma concentrate reservoir 40. The higher the centrifugal force applied, the more effective will be the stripping of the plasma concentrate from the surface of the gel beads. After centrifugation is completed, the device is removed from the centrifuge.

FIG. 9 shows the device with the plasma concentrate in the reservoir. The plasma concentrate is then drawn from the plasma concentrate reservoir through conduit to the plasma concentrate outlet.

The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the invention, and all such modifications are intended to be included within the scope of the invention.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3723244Jan 18, 1971Mar 27, 1973Atomic Energy CommissionFibrous fibrin sheet and method for producing same
US3850369Mar 8, 1973Nov 26, 1974Coulter ElectronicsCentrifuge for preparing platelet rich plasma
US3897343Feb 27, 1974Jul 29, 1975Becton Dickinson CoPlasma separator-hydrostatic pressure type
US3909419Feb 27, 1974Sep 30, 1975Becton Dickinson CoPlasma separator with squeezed sealant
US3931010Feb 27, 1974Jan 6, 1976Becton, Dickinson And CompanyPlasma separators with centrifugal valves
US3931018Aug 9, 1974Jan 6, 1976Becton, Dickinson And CompanyAssembly for collection, separation and filtration of blood
US3982691Oct 9, 1974Sep 28, 1976Schlutz Charles ACentrifuge separation and washing device and method
US4046699Nov 1, 1976Sep 6, 1977Corning Glass WorksAccess device for centrifugal separation assemblies
US4055501Jan 16, 1976Oct 25, 1977Sherwood Medical Industries Inc.Fluid collection device with phase partitioning means
US4077396Dec 2, 1976Mar 7, 1978Wardlaw Stephen CMaterial layer volume determination
US4154690Mar 15, 1978May 15, 1979Uwe BalliesDevice for use in the centrifugal separation of components of a liquid
US4187979Sep 21, 1978Feb 12, 1980Baxter Travenol Laboratories, Inc.Method and system for fractionating a quantity of blood into the components thereof
US4322298Jun 1, 1981Mar 30, 1982Advanced Blood Component Technology, Inc.Centrifugal cell separator, and method of use thereof
US4379849Sep 26, 1980Apr 12, 1983Ken HeimreidMethod and means for the examination of uncoagulated blood
US4416654Sep 3, 1981Nov 22, 1983Haemonetics CorporationPheresis apparatus
US4464167Aug 1, 1983Aug 7, 1984Haemonetics CorporationPheresis apparatus
US4675117Mar 20, 1985Jun 23, 1987Fresenius AgRecovering thrombocytes or leukocytes; circulation back to don or; efficiency/
US4714457Sep 15, 1986Dec 22, 1987Robert AlterbaumMethod and apparatus for use in preparation of fibrinogen from a patient's blood
US4776964Aug 24, 1984Oct 11, 1988William F. McLaughlinClosed hemapheresis system and method
US4818386Oct 8, 1987Apr 4, 1989Becton, Dickinson And CompanyDevice for separating the components of a liquid sample having higher and lower specific gravities
US5019243May 2, 1989May 28, 1991Mcewen James AApparatus for collecting blood
US5053127May 21, 1990Oct 1, 1991William F. McLaughlinContinuous centrifugation system and method for directly deriving intermediate density material from a suspension
US5131907Mar 6, 1991Jul 21, 1992Thomas Jefferson UniversityMethod of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
US5141645Jun 5, 1991Aug 25, 1992Terumo CorporationSeparate containers for each component
US5147290Dec 21, 1990Sep 15, 1992Stafilum AbMethod and machine based on the principle of centrifugation for cytapheresis such as platelet apheresis, and for plasma exchange treatment
US5165938May 18, 1990Nov 24, 1992Regents Of The University Of MinnesotaTopical treatment with cells
US5171456Jun 14, 1990Dec 15, 1992Baxter International Inc.Addition of anticoagulant to at least two different location through fluid flow path of the set; reduced incedence of citrate reaction in blood donar and increased platelet yield in platelet rich plasma collection
US5185001Jan 18, 1990Feb 9, 1993The Research Foundation Of State University Of New YorkMethod of preparing autologous plasma fibrin and application apparatus therefor
US5234608Dec 11, 1990Aug 10, 1993Baxter International Inc.Systems and methods for processing cellular rich suspensions
US5269927Dec 16, 1991Dec 14, 1993Sherwood Medical CompanySeparation device for use in blood collection tubes
US5271852May 1, 1992Dec 21, 1993E. I. Du Pont De Nemours And CompanyCentrifugal methods using a phase-separation tube
US5318782Feb 25, 1993Jun 7, 1994Weis Fogh Ulla SMethod for preparing tissue repair promoting substances
US5322620Aug 21, 1991Jun 21, 1994Baxter International Inc.Centrifugation system having an interface detection surface
US5344752Apr 7, 1993Sep 6, 1994Thomas Jefferson UniversityPlasma-based platelet concentrate preparations
US5370802Oct 22, 1992Dec 6, 1994Baxter International Inc.Enhanced yield platelet collection systems and methods
US5376263Nov 2, 1993Dec 27, 1994William F. McLaughlinPump control apparatus for cellular filtration systems employing rotating microporous membranes
US5387187Mar 1, 1994Feb 7, 1995Haemonetics CorporationRed cell apheresis method
US5403272May 29, 1992Apr 4, 1995Baxter International Inc.Apparatus and methods for generating leukocyte free platelet concentrate
US5456885Jul 12, 1993Oct 10, 1995Coleman; Charles M.Collecting and separating fluid having lighter and heavier specific gravity phases, dispensing lighter phase from tube having internal float of intermediate specific gravity which acts as check valve after centrifuging to retain heavy phase
US5494578Feb 22, 1994Feb 27, 1996Baxter International Inc.Centrifugation pheresis system
US5494592Jan 13, 1995Feb 27, 1996Haemonetics CorporationApheresis apparatus and method
US5501371Jul 7, 1994Mar 26, 1996Schwartz-Feldman; JeanMixing syringe
US5549683Apr 28, 1994Aug 27, 1996Bonutti; Peter M.Anthroplasty component
US5560830Dec 13, 1994Oct 1, 1996Coleman; Charles M.Water swellable coating on float; sealing tube
US5585007Dec 7, 1994Dec 17, 1996Plasmaseal CorporationPlasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US5601727Nov 3, 1992Feb 11, 1997Pall CorporationDevice and method for separating plasma from a biological fluid
US5607579Sep 28, 1995Mar 4, 1997Haemonetics CorporationApheresis apparatus for separating an intermediate density component from whole blood
US5614106Jun 2, 1995Mar 25, 1997Baxter International Inc.Method and apparatus for collection of platelets
US5632895Aug 11, 1994May 27, 1997Nigata Engineering Co., Ltd.Serum separating device and apparatus for serum separation
US5632905Aug 7, 1995May 27, 1997Haynes; John L.Method and apparatus for separating formed and unformed components
US5649903Jan 17, 1995Jul 22, 1997Baxter International Inc.Apparatus and methods for generating leukocyte free platelet concentrate
US5707331May 5, 1995Jan 13, 1998John R. WellsAutomatic multiple-decanting centrifuge
US5707876Mar 25, 1996Jan 13, 1998Stephen C. WardlawMethod and apparatus for harvesting constituent layers from a centrifuged material mixture
US5733466Feb 6, 1996Mar 31, 1998International Business Machines CorporationElectrolytic method of depositing gold connectors on a printed circuit board
US5733545Feb 27, 1996Mar 31, 1998Quantic Biomedical PartnersMixture containing plasma, fibrinogen, platelets and white cells
US5788662Oct 22, 1996Aug 4, 1998Plasmaseal LlcSurgical adhesive
US5795571Nov 15, 1996Aug 18, 1998Bristol-Myers Squibb CompanyCoagulation
US5795751Sep 30, 1996Aug 18, 1998Lockheed Martin Idaho Technologies CompanyBiofilter for removal of nitrogen oxides from contaminated gases under aerobic conditions
US5817519Nov 1, 1996Oct 6, 1998Bayer CorporationAutomated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples
US5833866Feb 26, 1997Nov 10, 1998Baxter International Inc.For separating platelets from blood; derives yield of platelets in real time
US5834418Mar 20, 1996Nov 10, 1998Theratechnologies, Inc.Process for the preparation of platelet growth factors extract
US5837150Jun 7, 1995Nov 17, 1998Cobe Laboratories, Inc.Selecting packing factor for separated blood component types in the separation stage of blood processing vessel
US5863892Jun 9, 1994Jan 26, 1999Allergan Inc.Use of platelet derived growth factor in ophthalmic wound healing
US5865785Feb 23, 1996Feb 2, 1999Baxter International Inc.Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes
US5899874Apr 30, 1993May 4, 1999Stiftelsen For Medicinsk-Teknisk UtvecklingMethod for recovering a platelet concentrate from blood
US5900245Sep 23, 1996May 4, 1999Focal, Inc.Compliant tissue sealants
US5934803Oct 30, 1997Aug 10, 1999Physical Systems, Inc.Apparatus and method for mixing multi-part reaction materials under vacuum
US5938621Sep 12, 1997Aug 17, 1999Becton Dickinson And CompanyCollection container assembly
US5955032Sep 12, 1997Sep 21, 1999Becton Dickinson And CompanyCollection container assembly
US5955436Dec 19, 1994Sep 21, 1999Alcon Laboratories, Inc.Topically administering to corneal wounds
US5958250Jul 18, 1997Sep 28, 1999Baxter International Inc.Blood processing systems and methods which optically derive the volume of platelets contained in a plasma constituent
US5958253Nov 6, 1997Sep 28, 1999Bristol-Myers Squibb CompanyCentrifuge reagent delivery method
US5980734Sep 11, 1998Nov 9, 1999Itoh; TeruakiAuxiliary apparatus for sampling blood serum
US6010627Jun 19, 1996Jan 4, 2000Quantic Biomedical PartnersDevice for concentrating plasma
US6022306Sep 5, 1997Feb 8, 2000Cobe Laboratories, Inc.Method and apparatus for collecting hyperconcentrated platelets
US6025201Jun 27, 1997Feb 15, 2000Bayer CorporationAutomated method for accurately discriminating platelets from non-platelet particles or cells on a cell-by-cell basis in a normal or an abnormal whole blood sample and for determining qualitative and quantitative blood platelet parameters
US6027655Aug 4, 1998Feb 22, 2000Bristol-Myers Squibb CompanyUsed for separating blood into phase portions having different densities by centrifugal separation and forming a fibrin monomer
US6051146Jan 20, 1998Apr 18, 2000Cobe Laboratories, Inc.Fluidizing a bed of first particles in carrier liquid to retain second particles within a rotating fluid chamber, diluting with lower density liquid to reduce overall density of separated particles and control coriolis force jetting
US6051147Dec 30, 1998Apr 18, 2000Baxter International Inc.Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes
US6053856May 8, 1997Apr 25, 2000Cobe LaboratoriesTubing set apparatus and method for separation of fluid components
US6054122Jun 7, 1995Apr 25, 2000The American National Red CrossA foamable fibrin matrix comprising fibrinogen or metabolite and an foaming agent which causes fibrinogen to foam during application of fibrinogen to wounded tissue
US6063297Aug 3, 1998May 16, 2000Plasmaseal LlcSeparation of blood cells from liquid suspension
US6063624Jun 9, 1997May 16, 2000Baxter International Inc.Separating platelet-rich plasma from whole blood, separating platelets from plasma, resuspending said platelet concentrate in a hypertonic solution of sodium chloride or potassium chloride; for storage or transfusion
US6071421Nov 25, 1997Jun 6, 2000Baxter International Inc.Conveying the suspension of platelets from the centrifugal separation chamber to a filter, while maintaining the intermediate layer containing leukocytes inside the centrifugal separation chamber.
US6071422May 26, 1998Jun 6, 2000Cobe Laboratories, Inc.Additive substances alter sedimentation velocity of the first particles to modify the filtration characteristics of the saturated fluidized bed.
US6071423Dec 29, 1998Jun 6, 2000Baxter International Inc.Portable lightweight equipment capable of easy transport.
US6090793Feb 12, 1993Jul 18, 2000Monsanto Europe S.A.Non-mitogenic substance, its preparation and use
US6096309Jun 17, 1998Aug 1, 2000Cohesion Technologies, Inc.Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
US6117425Jun 7, 1995Sep 12, 2000The American National Red CrossSupplemented and unsupplemented tissue sealants, method of their production and use
US6196987Mar 30, 1998Mar 6, 2001Gambro, Inc.Extracorporeal blood processing methods and apparatus
US6197325Jun 7, 1995Mar 6, 2001The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and use
US6200287Sep 5, 1997Mar 13, 2001Gambro, Inc.Extracorporeal blood processing methods and apparatus
US6214338Apr 25, 2000Apr 10, 2001Plasmaseal LlcComprising platelets and platelet releasate, from 5 to 400 mg/ml of fibrinogen, and a physiologically acceptable carrier comprising water and physiologically acceptable inorganic and organic ions at a physiologically acceptable concentration
US6245900Feb 23, 1995Jun 12, 2001Kyowa Hakko Kogyo Co., Ltd.Polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino groups in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a maleic acid styrene polymer
US6274090Aug 5, 1998Aug 14, 2001Thermogenesis Corp.Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US6280400Dec 2, 1999Aug 28, 2001Becton Dickinson And CompanyDevice and method for separating component of a liquid sample
US6296602Mar 17, 1999Oct 2, 2001Transfusion Technologies CorporationMethod for collecting platelets and other blood components from whole blood
US6368298Jun 24, 1998Apr 9, 2002Roberto BerettaPreparing autologous fibrin glue
US6417004Feb 14, 2000Jul 9, 2002Helena Laboratories CorporationEnhancing clot detection in activated clotting time and other fibrin endpoint based tests
Non-Patent Citations
Reference
1Fibrostik(TM) Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
2Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
3International Search Report for PCT/US2006/003598 mailed Jan. 6, 2006 claiming benefit of U.S. Appl. No. 60/640,860, filed Feb. 7, 2005.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8187475 *Mar 6, 2009May 29, 2012Biomet Biologics, LlcMethod and apparatus for producing autologous thrombin
Classifications
U.S. Classification210/782, 436/177, 422/44, 436/178, 210/219, 210/297, 422/72, 210/806, 210/502.1
International ClassificationB01D33/27, B01D37/00, B01D15/02
Cooperative ClassificationA61M1/02, A61M2202/0415, A61M1/3693, A61M1/3679
European ClassificationA61M1/02, A61M1/36P
Legal Events
DateCodeEventDescription
Jun 19, 2014FPAYFee payment
Year of fee payment: 4
Jun 17, 2009ASAssignment
Owner name: BIOMET BIOLOGICS, LLC, INDIANA
Free format text: CHANGE OF NAME;ASSIGNOR:BIOMET BIOLOGICS, INC.;REEL/FRAME:022834/0281
Effective date: 20080229
Jun 8, 2009ASAssignment
Owner name: BIOMET BIOLOGICS, INC., INDIANA
Free format text: CHANGE OF NAME;ASSIGNOR:CELL FACTOR TECHNOLOGIES, INC.;REEL/FRAME:022794/0587
Effective date: 20060216
Owner name: CELL FACTOR TECHNOLOGIES, INC., INDIANA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEACH, MICHAEL D.;REEL/FRAME:022794/0511
Effective date: 20060125
Owner name: HANUMAN, LLC, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DORIAN, RANDEL;REEL/FRAME:022794/0465
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STORRS, RICHARD W.;REEL/FRAME:022794/0435
Effective date: 20060124